Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clinical trial NCT06350097 · RECRUITING
Trial details
- NCT number
- NCT06350097
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-29
- Primary completion
- 2028-03-21
- Enrollment
- 582
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.